Quốc gia: Malta
Ngôn ngữ: Tiếng Anh
Nguồn: Medicines Authority
Bioton SA 5 Staroscinska Str. 02-516 Warsaw, Poland
A10AB01
INSULIN HUMAN (RDNA) 100 IU/ml
SOLUTION FOR INJECTION
INSULIN HUMAN (RDNA) 100 IU/ml
POM
DRUGS USED IN DIABETES
Authorised
2024-02-22
1 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT GENSULIN R 100 IU/ML SOLUTION FOR INJECTION _ _ _ Human insulin _ READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Gensulin R is and what it is used for 2. What you need to know before you use Gensulin R 3. How to use Gensulin R 4. Possible side effects 5. How to store Gensulin R 6. Contents of the pack and other information 1. WHAT GENSULIN R IS AND WHAT IT IS USED FOR Gensulin R contains the active substance human insulin, which is used to treat diabetes. You get diabetes if your pancreas does not make enough insulin to control the level of glucose in your blood (blood sugar). Gensulin R is used to control glucose in the long term. Gensulin R is a fast-acting insulin preparation. Your doctor may recommend you to use Gensulin R as well as a longer-acting insulin. Each kind of insulin comes with its own patient information leaflet to tell you about it. Do not change your insulin unless your doctor tells you to. Be very careful if you do change insulin. Each type of insulin has a different colour and symbol on the pack and the vial or the cartridge so that you can easily tell the difference. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE GENSULIN R GENSULIN R IN CARTRIDGES IS ONLY SUITABLE FOR SUBCUTANEOUS INJECTIONS FROM A REUSABLE PEN. GENSULIN R IN CARTRIDGES MUST NOT BE ADMINISTERED INTRAVENOUSLY OR INTRAMUSCULARLY. In case administration by syringe or intravenous injection or infusion pump is needed, a vial should be used. GENSULIN R IN VIA Đọc toàn bộ tài liệu
1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Gensulin R 100 IU/ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of Gensulin R solution contains 100 IU of soluble human insulin _(Insulinum humanum) _ obtained by _E. coli _ recombinant _ _ DNA technology process. Each cartridge for pen contains 3 ml of solution, corresponding to 300 IU of soluble insulin. Gensulin R contains human insulin only. The product is 100% consistent with the amino acid composition of the insulin produced by humans – unlike animal insulins or other insulin analogues obtained by genetic recombination whose compositions differ from human insulin to various extents.. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Gensulin R: solution for injection in a cartridge. Gensulin R is a sterile, clear, colourless aqueous solution of human insulin, adjusted to the pH range of 7.0-7.6. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS For the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis. 4.2. POSOLOGY AND METHOD OF ADMINISTRATION Posology Dosage is determined by the doctor according to patient’s insulin requirement. _Paediatric population _ No data are available. Method of administration subcutaneous use. GENSULIN R IN CARTRIDGES IS ONLY SUITABLE FOR SUBCUTANEOUS INJECTIONS FROM A REUSABLE PEN. GENSULIN R IN CARTRIDGES MUST NOT BE ADMINISTERED INTRAVENOUSLY OR INTRAMUSCULARLY. In case administration by syringe or intravenous injection or infusion pump is needed, a vial should be used. Gensulin R in vials is available on the market. Gensulin R can be used in intensive insulin therapy regimen as mealtime, prandial insulin. Subcutaneous administration should be in the upper arms, thighs, buttocks or abdomen. Use of injection sites should be rotated so that the same site is not used more than approximately once a 2 month in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see section 4.4 and 4 Đọc toàn bộ tài liệu